<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658810</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL20_1014</org_study_id>
    <nct_id>NCT04658810</nct_id>
  </id_info>
  <brief_title>Assessment of Post-traumatic Stress Disorder (PTSD) in Patients Monitored for Cytomegalovirus (CMV) Seroconversion During Pregnancy,</brief_title>
  <acronym>PTSD CMV</acronym>
  <official_title>Assessment of Post-traumatic Stress Disorder (PTSD) in Patients Monitored for Cytomegalovirus (CMV) Seroconversion During Pregnancy, Without Ultrasound Signs or With Non-serious Ultrasound Signs of Maternal-fetal CMV Infection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Reports of maternal seroconversion to CMV during pregnancy can be extremely stressful. This&#xD;
      virus is little known to the general public and searching for information on the Internet&#xD;
      quickly leads to a consultation of a site mentioning the risk of severe psychomotor&#xD;
      retardation in the event of prenatal cytomegalovirus infection.&#xD;
&#xD;
      The psychological repercussions in the event of prenatal CMV infection with criteria of&#xD;
      severity, leading or not to a request for IMG, is undeniable, but no study has investigated&#xD;
      the consequences of seroconversion to CMV without transmission of the virus to the patient&#xD;
      fetus, or in the case of transmission without criteria of seriousness, on the patient's&#xD;
      experience during and after her pregnancy. Such a study would, if necessary, improve the care&#xD;
      and support of these future mothers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PTSD evaluation</measure>
    <time_frame>Through study completion, 3 months</time_frame>
    <description>Assessment of post-traumatic stress disorder using the Perinatal Post-traumatic Stress Disorder scale (PPQ questionnaire)</description>
  </primary_outcome>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Mothers</condition>
  <condition>Cytomegalovirus Infections</condition>
  <condition>Pregnancy Related</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assessment of post-traumatic stress disorder using the Perinatal Post-traumatic Stress Disorder)</intervention_name>
    <description>Patients identified as women with cytomegalovirus (CMV) seroconversion during pregnancy will be called on the phoned and ask to participate to the study and to answer the Perinatal Post-traumatic Stress Disorder</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Assessment of post-traumatic stress disorder using the Perinatal Post-traumatic Stress&#xD;
        Disorder)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults&#xD;
&#xD;
          -  Referred to the 3 DAN centers with maternal seroconversion to CMV during their&#xD;
             pregnancy, confirmed, with or without confirmed prenatal transmission.&#xD;
&#xD;
          -  Presence of ultrasound signs without criteria of seriousness if the materno-fetal&#xD;
             infection is proven.&#xD;
&#xD;
          -  Support between January 1, 2008 and December 31, 2020.&#xD;
&#xD;
          -  No opposition from patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Reversed or anteconceptional CMV seroconversion&#xD;
&#xD;
          -  Concomitant infection with another infectious agent and suspected cross-reaction&#xD;
&#xD;
          -  Multiple pregnancy&#xD;
&#xD;
          -  Ultrasound and / or MRI severity criteria&#xD;
&#xD;
          -  Medical termination of pregnancy&#xD;
&#xD;
          -  Fetal death in utero&#xD;
&#xD;
          -  Birth &lt;32 weeks and / or birth weight &lt;1500 grams (birth criteria in maternity level&#xD;
             IIA)&#xD;
&#xD;
          -  Intercurrent event that may be the cause of an abnormality in psychomotor development&#xD;
&#xD;
          -  Patients protected by justice&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexis Fichez</last_name>
    <role>Principal Investigator</role>
    <affiliation>service de Gynécologie-Obstétrique, Hôpital de la Croix Rousse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexis Fichez, MD</last_name>
    <phone>(0)4 72 07 29 09</phone>
    <phone_ext>+33</phone_ext>
    <email>axel.fichez@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien Berthiller, CRA</last_name>
    <phone>(0)4 27 85 63 01</phone>
    <phone_ext>+33</phone_ext>
    <email>julien.berthiller@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Gynécologie Obstétrique, Hôpital Mère Enfant</name>
      <address>
        <city>Lyon</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona Massoud, MD</last_name>
      <phone>(0)427855169</phone>
      <phone_ext>+33</phone_ext>
      <email>mona.massoud@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Mona Massoud, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Gynécologie Obstétrique, Hôpital Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyrielle THONNON, MD</last_name>
      <phone>(0)478866588</phone>
      <phone_ext>+33</phone_ext>
      <email>cyrielle.thonnon@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Cyrielle THONNON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 1, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2020</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CMV</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>PTSD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

